PUBLISHER: DelveInsight | PRODUCT CODE: 1226609
PUBLISHER: DelveInsight | PRODUCT CODE: 1226609
"UX701 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about UX701 for Wilson's disease in the 7MM. A detailed picture of the UX701 for Wilson's disease in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the UX701 for Wilson's disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the UX701 market forecast, analysis for Wilson's disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Wilson's disease.
UX701 is an investigational AAV type 9 gene therapy designed to deliver a stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion. The therapy has been shown in preclinical studies to improve copper distribution and excretion from the body and reverse the pathological findings of Wilson liver disease. UX701 is currently in Phase I/II/III.
The company has also received FDA IND clearance, which allows for advancing this new gene therapy in the clinic and offers hope for a new treatment for patients with WD. UX701 has the potential to directly address the underlying basis of disease by restoring the normal transport and excretion of copper.
The therapy was granted Orphan Drug Designation in the United States and Europe.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
UX701 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of UX701 in Wilson's disease in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of UX701 for Wilson's disease covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions